About Diabetic Macular Edema (DME)DME, the primary cause of vision loss associated with diabetic retinopathy, is a disease affecting the macula, the part of the retina responsible for central vision. When the blood vessel leakage associated with diabetic retinopathy results in swelling of the macula, the condition is called DME. The onset of DME is painless and may go unreported by the patient until it manifests with the blurring of central vision or acute vision loss. The severity of this blurring may range from mild to profound loss of vision. The Wisconsin Epidemiologic Study of Diabetic Retinopathy found that over a 10-year period approximately 19% of people with diabetes included in the study were diagnosed with DME. All people with type 1 or type 2 diabetes are at risk of developing DME. About Alimera Sciences, Inc. www.alimerasciences.com Alimera, founded in June 2003, is a pharmaceutical company that specializes in the commercialization, research, and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera's commitment to retina specialists and their patients is manifest in Alimera's product and development portfolio designed to treat early- and late-stage diseases. For more information, please visit www.alimerasciences.com. For press inquiries:Katie Brazelfor Alimera Sciences email@example.com For investor inquiries:CG Capitalfor Alimera Sciences877firstname.lastname@example.org
ATLANTA, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, Chief Executive Officer of Alimera, will present at the Ophthalmology Innovation Summit (OIS) to be held Thursday, November 9, 2017 in conjunction with the 2017 American Academy of Ophthalmology (AAO) in New Orleans. Mr. Myers will be speaking as part of the Public Device and BioPharma Company Showcase scheduled for 3:35-4:45 p.m. OIS unites industry, entrepreneurial and clinical leaders to collaborate on the development and commercialization of innovative drugs and devices to address unmet clinical needs. At OIS@AAO, Mr. Myers will present real-world data from the USER (U.S. Retrospective Chart Review in Patients Receiving ILUVIEN ®) Study, as well as provide an update on Alimera's progress toward securing for ILUVIEN an indication for posterior uveitis in Europe. "We welcome the opportunity to discuss our accomplishments and our vision with other leaders in the ophthalmic industry at OIS," said Mr. Myers. "OIS@AAO is always a great day to highlight ILUVIEN and Alimera, especially now that we can share how the continuous microdosing of ILUVIEN provides a unique opportunity to treat DME consistently everyday by reducing the treatment frequency for physicians and patients." The slides used in Mr. Myers' presentation will be posted on the Alimera website, www.alimerasciences.com, prior to the meeting. About ILUVIEN www.ILUVIEN.com. ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is a sustained release intravitreal implant approved in the U.S. to treat diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. Each ILUVIEN implant is designed to release submicrogram levels of fluocinolone acetonide, a corticosteroid, for 36 months to treat DME consistently every day.